These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766 [TBL] [Abstract][Full Text] [Related]
8. Statin Prescribing in the Elderly: Special Considerations. Leya M; Stone NJ Curr Atheroscler Rep; 2017 Oct; 19(11):47. PubMed ID: 29019063 [TBL] [Abstract][Full Text] [Related]
9. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124 [TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
11. Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial. Bonnet F; Bénard A; Poulizac P; Afonso M; Maillard A; Salvo F; Berdaï D; Salles N; Rousselot N; Marchi S; Hayes N; Joseph JP Trials; 2020 Apr; 21(1):342. PubMed ID: 32307005 [TBL] [Abstract][Full Text] [Related]
12. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Lim S; Sakuma I; Quon MJ; Koh KK Int J Cardiol; 2013 Sep; 167(5):1696-702. PubMed ID: 23159411 [TBL] [Abstract][Full Text] [Related]
13. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350 [TBL] [Abstract][Full Text] [Related]
14. Statins for the primary prevention of cardiovascular disease. Taylor F; Ward K; Moore TH; Burke M; Davey Smith G; Casas JP; Ebrahim S Cochrane Database Syst Rev; 2011 Jan; (1):CD004816. PubMed ID: 21249663 [TBL] [Abstract][Full Text] [Related]
15. Lipid lowering for secondary prevention of cardiovascular disease in older adults. Thomas JE; Tershakovec AM; Jones-Burton C; Sayeed RA; Foody JM Drugs Aging; 2010 Dec; 27(12):959-72. PubMed ID: 21087066 [TBL] [Abstract][Full Text] [Related]
16. A clinician's guide to statin drug-drug interactions. Kellick KA; Bottorff M; Toth PP; The National Lipid Association's Safety Task Force J Clin Lipidol; 2014; 8(3 Suppl):S30-46. PubMed ID: 24793440 [TBL] [Abstract][Full Text] [Related]
17. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]